



HAL
open science

Interactive effect between ATPase-related genes and early-life tobacco smoke exposure on bronchial hyper-responsiveness detected in asthma-ascertained families

Marie-Hélène Dizier, Patricia Margaritte-Jeannin, Lucile Pain, Chloé Sarnowski, Myriam Brossard, Hamida Mohamdi, Nolwenn Lavielle, Marie-Claude Babron, Jocelyne Just, Mark Lathrop, et al.

► To cite this version:

Marie-Hélène Dizier, Patricia Margaritte-Jeannin, Lucile Pain, Chloé Sarnowski, Myriam Brossard, et al.. Interactive effect between ATPase-related genes and early-life tobacco smoke exposure on bronchial hyper-responsiveness detected in asthma-ascertained families. *Thorax*, 2019, 74 (3), pp.254-260. 10.1136/thoraxjnl-2018-211797 . inserm-02939798

HAL Id: inserm-02939798

<https://inserm.hal.science/inserm-02939798>

Submitted on 15 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Interactive effect between ATPase-related genes and early-life tobacco smoke**
2 **exposure on bronchial hyper-responsiveness detected in asthma-ascertained**
3 **families**

4 Marie-Hélène Dizier^{1,2}, PhD, Patricia Margaritte-Jeannin^{1,2}, PhD, Lucile Pain³, MSc,
5 Chloé Sarnowski^{1,2}, PhD, Myriam Brossard^{1,2}, PhD, Hamida Mohamdi^{1,2}, MSc,
6 Nolwenn Lavielle^{1,2}, MSc, Marie-Claude Babron^{1,2}, PhD, Jocelyne Just⁴, MD, PhD,
7 Mark Lathrop⁵, PhD, Catherine Laprise^{**3}, PhD, Emmanuelle Bouzigon^{**1,2}, MD,
8 PhD, Florence Demenais^{*1,2}, MD, Rachel Nadif^{*6,7}, PhD,

9 *: these authors contributed equally

10 **: these authors contributed equally

11

12 1. Inserm, UMR-946, Genetic Variation and Human Diseases unit, F-75010, Paris,

13 France;

14 2. Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, F-
15 75007, Paris, France;

16 3. Université du Québec, Chicoutimi, Canada ;

17 4. Service d'Allergologie Pédiatrique, Centre de l'Asthme et des Allergies. Hôpital
18 d'Enfants Armand-Trousseau (APHP), UPMC Paris 06, F-75012, Paris, France;

19 5. Mc Gill University and Genome Quebec's Innovation Centre, Montréal, Canada;

20 6. Inserm, U1168, Aging and chronic diseases. Epidemiological and public health
21 approaches (VIMA), F-94807, Villejuif, France;

22 7. Univ Versailles Saint-Quentin-en-Yvelines, UMR-S 1168, France;

23

24 **Corresponding author**

25 Marie-Hélène DIZIER

26 UMR946, INSERM / Université Paris-Diderot

27 27 rue Juliette Dodu

28 F-75010 Paris, France

29 Phone +33 1 72 63 93 25

30 Fax +33 1 72 63 93 49

31 Marie-Helene.Dizier@inserm.fr

32

33 **Running title:**

34 ATP genes and early-life smoking exposure in BHR

35

36 **Key messages:**

37 What is the key question?

38 Could genes belonging to ATP-related pathways interact with exposure to early-life

39 tobacco smoke exposure on bronchial hyper-responsiveness?

40

41 What is the bottom line?

42 Gene x Environment interaction analyses with ATP-related genes allowed to identify

43 promising candidate genes, ATP8A1 and ABCA1, interacting with early-life tobacco

44 smoke exposure in bronchial hyper-responsiveness susceptibility.

45

46 Why read on?

47 The present study highlights that Gene x Environment interaction analyses under a

48 pathway-based strategy can greatly contribute to the identification of novel genes

49 involved in complex disease as bronchial hyper-responsiveness.

50

51 **ABSTRACT**

52 Background: A positional cloning study of bronchial hyper-responsiveness (BHR) at the
53 17p11 locus in the French Epidemiological study on the Genetics and Environment of
54 Asthma (EGEA) families showed significant interaction between early life
55 environmental tobacco smoke (ETS) exposure and genetic variants located in *DNAH9*.
56 This gene encodes the heavy chain subunit of axonemal dynein, which is involved with
57 adenosine triphosphate (ATP) in the motile cilia function.

58 Our goal was to identify genetic variants at other genes interacting with ETS in BHR by
59 investigating all genes belonging to the “*ATP-binding*” and “*ATPase activity*” pathways
60 which include *DNAH9*, are targets of cigarette smoke and play a crucial role in the
61 airway inflammation.

62 Methods: Family-based interaction tests between ETS exposed *versus* unexposed BHR
63 siblings were conducted in 388 EGEA families. Twenty SNPs showing interaction
64 signals ($P \leq 5.10^{-3}$) were tested in the 253 Saguenay-Lac-Saint-Jean (SLSJ) families.

65 Results: One of these SNPs was significantly replicated for interaction with ETS in
66 SLSJ families ($P=0.003$). Another SNP reached the significance threshold after
67 correction for multiple testing in the combined analysis of the two samples ($P=10^{-5}$).

68 Results were confirmed using both a robust log-linear test and a gene-based interaction
69 test.

70 Conclusion: The SNPs showing interaction with ETS belong to the *ATP8A1* and *ABCA1*
71 genes, which play a role in the maintenance of asymmetry and homeostasis of lung
72 membrane lipids.

73

74 **Key words:** BHR, FBAT, ETS, GxE interaction, ATP, asthma

75 Key message: *ATP8A1* and *ABCA1* genes interact with early-life tobacco smoke
76 exposure in BHR in asthma-ascertained families.

77

78

79 INTRODUCTION

80 Bronchial hyper-responsiveness (BHR) is both a feature and an important risk factor for
81 asthma [1]. The susceptibility genes for asthma and BHR [2], identified to date, account
82 for a relatively small proportion of the genetic component of these phenotypes [3]. As
83 asthma and BHR are complex diseases which result from both genetic and
84 environmental factors, the effect of genetic factors may be missed if they are tested
85 individually, i.e. by ignoring gene by environment (GxE) interactions. Furthermore,
86 taking into account the biological function shared by genes or pathways they are
87 involved in may help discovering new genes [4].

88 Maternal smoking during pregnancy and early life environmental tobacco smoke (ETS)
89 exposure are well-known risk factors for asthma and BHR [5]. Gene x ETS interaction
90 underlying susceptibility to asthma and asthma-related phenotypes have been evidenced
91 by positional cloning studies which detected *PCDHI* (protocadherin 1) and *ADAM33*
92 (ADAM metallopeptidase domain 33) genes [6, 7, 8], by association studies with
93 candidate genes including *ADRB2* (β 2-adrenergic receptor) [9], and by interaction
94 analysis with genetic variants at the 17q12-21 locus discovered by the first asthma
95 GWAS [10, 11]. More recently, a meta-analysis of genome-wide interaction studies
96 (GEWIS) for childhood asthma [12] suggested interaction between ETS exposure and
97 *PACRG* (Parkin coregulated) - a gene having a role in motile cilia function.

98 In the French Epidemiological study on the Genetics and Environment of Asthma
99 (EGEA) families, we previously performed a positional cloning study in the 17p11
100 region that showed interactive effect between ETS and *DNAH9* (Dynein, Axonemal,
101 Heavy Chain 9) [13, 14] genetic variant on BHR. This gene encodes the heavy chain
102 subunit of axonemal dynein, a component responsible for cilia mobility. Interestingly, a

103 recent study of atopy, another asthma-related phenotype, showed significant interaction
104 between *DNAH5*, a gene of the same family as *DNAH9*, and *ADGRV1* (adhesion G
105 protein-coupled receptor V1), both genes being involved in ciliary function [15].
106 Overall, these findings suggest that ciliary dysfunction may represent a novel
107 mechanism underlying asthma-related phenotypes.

108 The heavy chain subunit of axonemal dynein contains all of the elements that are
109 needed to convert the energy into movement though a process in which dynein,
110 adenosine triphosphate (ATP) binding and ATP hydrolysis are involved [16, 17, 18].
111 Interestingly, in asthmatic patients, ATP was shown to be accumulated in the airways
112 and to trigger HRB, suggesting an important role played by ATP in the airway
113 inflammation [19]. Moreover, ATP-binding cassette (ABC) transporters were
114 implicated in pulmonary lipid homeostasis and inflammation, indicating a crucial and
115 protective role in lung [20].

116 Smoking and exposure to cigarette smoke have been shown to affect the number and
117 function of human bronchial cilia [18, 21], while a significant loss of Na,K-ATPase
118 activity was observed in human lung cell lines exposed to cigarette smoke [22] and in
119 platelet membrane in cigarette smokers compared to controls [23].

120

121 In the present study, we hypothesized that genes belonging to *ATPase activity*” and
122 “*ATP binding*” pathways, the two ATP-related pathways that include *DNAH9*, may also
123 interact with exposure to ETS in BHR. We tested for interaction all genes of these two
124 pathways using the discovery sample of 388 French EGEA families, ascertained
125 through asthmatic probands. We first applied FBAT (Family-Based Association Test)
126 [24] homogeneity test between exposed *versus* unexposed BHR siblings to detect

127 interactions for SNPs located in the genes belonging to the two pathways. Replication
128 of results was sought in an independent sample of 253 French-Canadian asthma-
129 ascertained families. We also validated our results by using another SNP x E interaction
130 test based on log-linear modeling case-parent triads [25], and finally by gene-based
131 interaction analysis.

132

133 MATERIAL AND METHODS

134 Discovery sample

135 The EGEA study and inclusion criteria have been described in detail previously [26].
136 The EGEA family sample consisted of 388 French nuclear families that included 253
137 families ascertained through offspring with asthma (one offspring proband in 90% of
138 families and two offspring probands in the remainder) and 135 families ascertained
139 through one parent with asthma. Ethical approval was obtained from the relevant
140 institutional review board committees (Cochin Port-Royal Hospital and Necker-Enfants
141 Malades Hospital, Paris). Written informed consent was signed by all participants or by
142 kin or guardians of the minors/children.

143 The BHR phenotype was defined according to the results of the methacholine bronchial
144 challenge test, as done previously [13, 14]. Participants who had a fall in their baseline
145 FEV₁ (forced expiratory volume in 1s) $\geq 20\%$ at ≤ 4 mg/ml of methacholine (PD20) had
146 BHR while participants that did not show a fall in FEV₁ did not have BHR. The
147 protocol of the methacholine challenge test has been described in detail elsewhere [26].
148 The ETS exposure in early-childhood was defined, as previously [10, 13, 14] through
149 questionnaires: 1) for an adult, by a positive answer to the question: "*Did your mother*
150 *or your father smoke during your early-childhood?*", 2) for a child, by a positive answer
151 to the question asked to the child's mother (or father): "*Did you or the father (or the*
152 *mother) of your child smoke when your child was less than 2 years old?*". We did not
153 use information on *in-utero* exposure to tobacco-smoke since all mothers who smoked
154 during pregnancy continued to smoke during the early childhood of their offspring.

155

156

157 **Replication study**

158 The Saguenay-Lac-Saint-Jean (SLSJ) asthma study comprised 253 French-Canadian
159 multigenerational families ascertained through two probands with asthma [27].
160 Inclusion criteria of probands have been described previously [27]. The SLSJ local
161 ethics committee approved the study, and all subjects gave informed consent.
162 The BHR (PD20) phenotype and ETS exposure were defined in SLSJ in an identical
163 manner as in the EGEA study.

164

165 **Genotyping**

166 The EGEA subjects were genotyped using Illumina 610 Quad array (Illumina, San
167 Diego, CA) at the Centre National de Génomique (CNG, Evry, France), as part of the
168 European Gabriel consortium asthma GWAS [28]. Stringent quality control criteria, as
169 detailed previously [28], were used to select both individuals and genotyped SNPs for
170 analysis. For this study, we selected from the Gene Ontology (GO) database
171 (<http://amigo.geneontology.org/>) 296 genes belonging to both molecular functions
172 “ATPase binding” (GO: 0005524) and “ATPase activity” (GO: 0016887) and the
173 corresponding 4,252 SNPs located within these genes (see Supplementary Table S1).

174 The SLSJ sample was also genotyped at CNG using the Illumina 610 Quad array. The
175 same quality control criteria for individuals and SNPs as those used for EGEA were
176 applied to this dataset.

177

178 **Statistical analysis**

179 GxE interaction analysis using FBAT-homogeneity test

180 *Analysis of the EGEA discovery sample*

181 Analyses were conducted using the FBAT approach [24], which tests for association in
182 presence of linkage. We assumed an additive genetic model and used the option for an
183 empirical estimator of the variance [29], which makes the association test robust to the
184 dependency between siblings and allows use of all siblings in a family. FBAT was
185 applied separately to ETS exposed and unexposed siblings. We searched for SNP x ETS
186 interaction by testing homogeneity of FBAT association results between ETS exposed
187 and unexposed [30]. Note that after exclusion of SNPs leading to insufficient sample
188 size (<30) of informative families for FBAT analyses in the EGEA sample, only 4,112
189 SNPs belonging to only 266 genes were analysed.

190

191 *Replication analysis with the SLSJ sample*

192 SNPs showing interaction signals ($P \leq 5 \times 10^{-3}$) in the EGEA sample were followed-up in
193 the SLSJ sample. The arbitrary threshold of $5 \cdot 10^{-3}$ was chosen to obtain both a strong
194 indication of association and a reasonable number of SNPs (here 20, see results) tested
195 in the replication dataset. For replication study of these SNPs detected in EGEA, both
196 analysis in SLSJ and combined analysis in EGEA and SLSJ were conducted.

197 First, analyses were conducted in SLSJ and results were declared as significant if they
198 meet the Bonferroni corrected significance P -threshold applied to the M_{eff} (effective
199 number of independent tests after discarding dependence due to Linkage Disequilibrium
200 (LD) between the SNPs) [31] calculated from the 20 SNPs tested in SLSJ. The M_{eff}
201 was estimated to 15 and thus the significance P -threshold equal to $3 \cdot 10^{-3}$.

202 Second, combined FBAT analysis of the EGEA and SLSJ samples was conducted,
203 separately in ETS exposed and unexposed siblings using the Stouffer's Z -score method,
204 and homogeneity test was applied between exposed vs unexposed siblings to the

205 combined results. The results of this combined analysis are not independent from the
206 results obtained in EGEA. We thus declared results as significant if they meet the
207 significance P -threshold ($P=2.10^{-5}$), calculated after correction for multiple tests by the
208 Bonferroni correction applied to the Meff (2500) estimated from the total number of
209 SNPs tested in EGEA.

210

211 *Validation analysis using Umbach and Weinberg method*

212 In order to validate the significant interactions found with the FBAT homogeneity test,
213 we applied, the log-linear modeling approach for testing interaction in triads (case and
214 parents), as proposed by Umbach and Weinberg (UW) [25], to the pooled sample of
215 EGEA and SLSJ. This approach allows adjusting on the genotypic parental mating of
216 each sibling and thus avoids bias due to population stratification. A different
217 distribution of parental genotypic matings between exposed *versus* unexposed siblings,
218 due to population stratification, may lead to different transmission probabilities in the
219 two groups and consequently to false detection of interaction. FBAT is less robust
220 because it only adjusts for the genotypic parental distribution within the exposed and
221 unexposed groups of siblings. However, the UW method is less powerful than FBAT
222 because it can be applied to only one sib per family. The log-linear analysis was
223 conducted using the youngest siblings for whom the information on ETS exposure was
224 the closest in time with respect to BHR occurrence and thus the less influenced by a
225 potential recall bias. The analysis was also performed by considering the oldest siblings,
226 but similar results were obtained and are thus not presented.

227 As for FBAT analysis, all UW analyses assumed an additive genetic model and the
228 same correction for multiple testing was applied, *i.e.* Bonferroni correction applied to
229 the Meff of 2,500.

230

231 *Gene-based analysis*

232 For each of the 266 genes, interactions with ETS exposure in BHR were also
233 investigated at the gene level by using the versatile gene-based test (VEGAS) [32] .
234 The gene-based statistic was defined as the best SNP test statistic (or min P value) using
235 the results of FBAT-homogeneity tests in the combined analysis of EGEA and SLSJ
236 samples. Empirical P -value of the gene-based statistic was computed through Monte-
237 Carlo simulations using the linkage-disequilibrium pattern of HapMap CEU reference
238 sample. The empirical P -values were adjusted for multiple testing using the Bonferroni
239 correction (significance P -threshold= $0.05/266=2.10^{-4}$).

240

241 *Expression Quantitative Trait loci (eQTL) analysis, functional annotation and* 242 *chemical-gene/protein interactions*

243 We investigated whether the SNPs (or their proxies, $r^2 \geq 0.8$) found to interact with ETS
244 were cis-expression quantitative trait loci (cis-eQTLs). We used the GTEx browser
245 (<http://www.gtexportal.org/home/>) [33], that includes e-QTL data from many tissues.
246 Functional annotations of these SNPs (or proxies) were done using the HaploReg tool
247 (<http://www.broadinstitute.org/mammals/haploreg/haploreg.php>). HaploReg annotates
248 SNPs in terms of co-localization with regulatory elements, such as promoter and
249 enhancer marks, DNase I hypersensitivity sites, and transcription factor (TF) and

250 protein binding sites, based on ROADMAP and ENCODE (ENcyclopedia Of DNA
251 Elements) data.

252 Furthermore, curated [chemical–gene interactions|chemical–disease|gene–disease] data
253 were retrieved from the Comparative Toxicogenomics Database (CTD) [34], MDI
254 Biological Laboratory, Salisbury Cove, Maine, and NC State University, Raleigh, North
255 Carolina. World Wide Web, (URL: <http://ctdbase.org/>). [May, 2018]. CTD is a robust,
256 publicly available database that aims to advance understanding about how
257 environmental exposures affect human health. It provides manually curated information
258 about chemical–gene/protein interactions, chemical–disease and gene–disease
259 relationships.

260

261

262 **RESULTS**263 **Data description**

264 The characteristics of genotyped siblings having BHR in EGEA and SLSJ families are
265 shown in Table 1.

266 Table 1: Phenotypic features of genotyped siblings having BHR in EGEA and SLSJ
267 asthma-ascertained families
268

	EGEA	SLSJ
N siblings	304	145
Age, years, mean (SD)	16.1 (8.1)	20.3 (10.3)
Sex, n (%) women	132 (43.4)	76 (52.4)
Asthma, n (%)	181 (59.5)	138 (95.2)
Age at asthma onset, years, mean (SD)	7.4 (7.7)	9.4 (9.3)
Allergic sensitization*, n (%)	228 (76.0)	121 (85.8)
ETS** exposure, n (%)	176 (57.9)	93 (64.1)

269 *: allergic sensitization: a positive response of skin prick test to at least one allergen.

270 **: ETS: Environmental tobacco smoke.

271

272 Three hundreds and four siblings (from 189 families) had BHR in EGEA and 145 (from
273 120 families) in SLSJ. They were younger in EGEA than in SLSJ with respective mean
274 ages equal to 16.1 and 20.3 years ($P < 10^{-4}$). The proportion of siblings with allergic
275 sensitization was similar in the two datasets (76% in EGEA and 86% in SLSJ), while
276 the proportion of asthmatics was higher in SLSJ (95%) than in EGEA (60%) ($P < 10^{-4}$).
277 The proportion of female was similar in the two datasets (43% in EGEA and 52% in
278 SLSJ). The mean age at onset of asthma was slightly lower in EGEA (7.4) than in SLSJ
279 (9.4) ($P = 0.05$). Finally, the proportion of exposed siblings was similar in EGEA and in
280 SLSJ (58% *versus* 64% respectively).

281 **Analysis of Gene x ETS interactions using FBAT-homogeneity test**

282 The results in the EGEA, SLSJ, and combined samples are shown in Table 2 (for more
283 details see Supplementary Table S2).

284 Table 2: Results of FBAT-homogeneity test in the EGEA and SLSJ samples for SNPs
285 detected in EGEA with $P \leq 5.10^{-3}$.

						EGEA	SLSJ	EGEA+SLSJ#
Chr	SNP	Gene	Location	Position* (kb)	MAF**	P	P	P
1	rs10924249	KIF26B	flanking_3UTR	243837	0.18	0.004	0.302	0.059
2	rs6736802	KIF5C	flanking_5UTR	149566	0.43	0.002	0.320	0.056
2	rs6435220	KIF5C	flanking_5UTR	149569	0.31	0.003	0.659	0.032
4	rs1460354	ATP8A1	Intron	42266	0.22	0.001	0.115	6.0E-04
4	rs13124088	ATP8A1	Intron	42280	0.20	0.005	0.227	0.004
4	rs17448506	ATP8A1	Intron	42343	0.27	1.7E-05	0.133	1.2E-05
6	rs160666	WRNIP1	flanking_3UTR	2719	0.32	0.003	0.398	0.041
8	rs2279444	KIF13B	Intron	29053	0.15	0.005	0.400	0.006
9	rs2253304	ABCA1	Intron	106658	0.27	0.004	0.003	6.1E-05
9	rs2253182	ABCA1	Intron	106659	0.27	0.004	0.005	9.2E-05
9	rs2253175	ABCA1	Intron	106660	0.27	0.004	0.004	7.2E-05
9	rs2253174	ABCA1	Intron	106660	0.27	0.004	0.004	7.2E-05
9	rs2230805	ABCA1	Coding	106663	0.25	0.005	0.017	2.0E-04
11	rs762667	MYO7A	Coding	76546	0.38	0.002	0.446	0.003
16	rs2914819	ATP2C2	Intron	83026	0.19	0.003	0.353	0.0018
17	rs7225157	DNAH9##	Intron	11621	0.17	8.1E-04	0.038	6.8E-05
18	rs12458154	ATP9B	Intron	75187	0.28	0.002	0.551	0.0047

20	rs6067867	ATP9A	Intron	49698	0.46	0.005	0.376	0.0056
20	rs6067892	ATP9A	Intron	49731	0.47	0.002	0.410	0.0036
20	rs1475670	ATP9A	Intron	49777	0.50	0.004	0.058	7.0E-04

286 *: SNP position in kilobase (dbSNP, build 37.1)

287 **: estimated in EGEA

288 #: combined analysis of the EGEA and SLSJ samples using the Stouffer's Z-score
289 method

290 ##: previously detected by our positional cloning [14]

291 Significant results are in bold

292

293 FBAT-homogeneity test in EGEA detected 20 SNPs (at the level of $P \leq 5 \cdot 10^{-3}$), for

294 which replication study was then conducted. The analysis in SLSJ detected a significant

295 association ($P = 3 \cdot 10^{-3}$) with one of these SNPs, rs2253304 which is located in *ABCA1*

296 intron. The combined analysis of the two EGEA and SLSJ samples detected another

297 SNP, rs17448506 which is located in *ATP8A1* intron, and reached the significance

298 threshold for interaction with ETS ($P = 10^{-5}$). The SNP rs2253304 was also the second

299 top signal in the combined analysis ($P = 6 \cdot 10^{-5}$).

300 At both SNPs, there was a "Flip-Flop" interaction effect (i.e. an inverse effect

301 depending on exposure): the C allele (*versus* T allele) of rs17448506 was positively

302 associated with BHR in ETS-exposed siblings and negatively in ETS-unexposed

303 siblings, while G allele (*versus* A allele) of rs2253304 was positively associated with

304 BHR in ETS-exposed siblings and negatively in ETS-unexposed siblings.

305

306 **Validation analysis using Umbach and Weinberg method**

307 For the two SNPs retained by the analyses based on FBAT homogeneity test

308 (rs17448506 and rs2253304), results of UW analysis in the pooled EGEA and SLSJ

309 samples are presented in Table 3.

310 Table 3: Results with UW in the pooled sample of EGEA and SLSJ for SNPs detected
 311 by FBAT-homogeneity test:

312

Chr	SNP	Gene	Location	Position * (kb)	MAF	<i>P</i>
4	rs17448506	ATP8A1	intron	42343	0.27	9.0E-04
9	rs2253304	ABCA1	intron	106658	0.27	5.0E-04

313 *: SNP position in kilobase (dbSNP, build 37.1)

314

315 Both SNPs showed quite strong signals of interaction ($P \leq 10^{-3}$) with the UW method,
 316 although they did not reach the significance threshold of 2×10^{-5} .

317

318 Gene-based analysis

319 Results by the gene-based test using the combined results of EGEA and SLSJ were
 320 given for all 266 genes in Supplementary Table S3. *ATP8A1* and *ABCA1* were the first
 321 and third top genes, respectively, interacting with ETS exposure in BHR that were
 322 detected ($P=3.10^{-4}$ and $P=3.10^{-3}$, respectively). Only the *P*-value for *ATP8A1* was close
 323 to the significance threshold of 2.10^{-4} adjusted for multiple testing. The second top gene
 324 was *ATP9B* and the 4th top gene *DNAH9*.

325

326 eQTL, Functional Annotations and Chemical–Gene/Protein Interactions

327 No eQTL was found among the SNPs (or proxies) interacting with ETS at *ATP8A1* and
 328 *ABCA1* loci. Using the functional annotation tool HaploReg-v4.1, we found that both
 329 SNPs map to enhancer and promoter histone marks and that rs2253304 and its proxies
 330 map to DNase hypersensitivity sites, notably in fetal lung fibroblasts cell line, Lung
 331 Carcinoma Cell Line and Lung Fibroblast Primary Cells. They also map to binding sites

332 of many transcription factors including the redox-sensitive nuclear factor (NF)-kappaB
333 (NF-κB) for rs17448506 and the Histone Deacetylase 2 (HDAC2), Activator Protein 1
334 (AP-1), Smad and STAT for rs2253304 and proxies.

335 Further, from the Comparative Toxicogenomics Database, we found that tobacco smoke
336 pollution and soot have been reported to modify the expression of *ATP8A1* and *ABCA1*
337 mRNA (see Table S4). We also found that air pollutant exposures known to contain
338 compounds with irritant properties such as in tobacco smoke modified the expression of
339 *ABCA1* (see Table S4).

340

341 **DISCUSSION**

342 This study identified genetic variants at two novel loci, in chromosomes 4 and 9,
343 interacting with ETS exposure in BHR. After a selection of SNPs showing signal of
344 interaction with ETS in EGEA, interaction was significantly replicated in SLSJ for a
345 first SNP intronic to *ABCA1* gene. Significant interaction with ETS was detected for a
346 second SNP intronic to *ATP8A1* gene in the combined analysis of EGEA and SLSJ
347 samples. Furthermore, in the gene-based analysis, *ATP8A1* and *ABCA1* were among the
348 three top genes interacting with ETS exposure, this interaction being very close to the
349 significance level for *ATP8A1*.

350 Most of previous interaction studies of genetic variants with ETS on BHR or asthma
351 risk had difficulties to show significant interaction and/or replication in independent
352 samples [6, 12, 35]. Indeed, replication of GxE interaction is much more difficult to
353 achieve than replication of single SNP association. It is well-recognized that interaction
354 tests have low power. Moreover, replication of interaction is affected by heterogeneity
355 not only in the outcome but also in exposure definition of the participating studies. The
356 distribution of exposure may also differ across populations and therefore change the
357 potential to identify the interaction. It is well-known that ETS is influenced by
358 socioeconomic position and generation effect. Tobacco use seems to be almost
359 universally more prevalent in low socioeconomic groups than in high socioeconomic
360 groups [36]. Over the last ten years, the prevalence of ETS exposure at home among
361 children and the percentage of children whose parents smoke has declined in several
362 industrialized countries [37]. Difference in the distribution of ETS may thus result in
363 different relationships among the gene, environment and disease. It was difficult to find
364 replication samples that showed consistent definitions of BHR and ETS exposure and

365 similar distribution of ETS exposure with those of the EGEA discovery sample. Only
366 one replication sample from the SLSJ study showed similarities with EGEA in terms of
367 ascertainment through asthmatic subjects, definition of both BHR and ETS, distribution
368 of ETS and genotype information available in parents and siblings. To keep reasonable
369 the number of tests and then limit the problem of low power of interaction test, we
370 examined only SNPs located within gene boundaries. Even if SNPs lying at some
371 distance upstream and downstream from the gene are often considered, the choice of
372 that distance is not obvious.

373 Nevertheless, we were able to identify two SNPs, with significant evidence for
374 interaction with ETS. These results were confirmed by the UW approach, which is more
375 robust although less powerful than FBAT as described above in the methods section.

376 Our study relies on an original strategy to select and enlarge a list of candidate genes.
377 Supported by biological knowledge, we think our pathway selection approach allows a
378 good tradeoff between GEWIS and candidate gene approaches, and offers the
379 possibility to identify new genes as we previously showed [4]. We cannot exclude that
380 our selection may lose a number of relevant genes that are not targeted by our analysis.

381 In particular, we choose the stringent option to investigate genes, which similarly to
382 *DNAH9*, belong simultaneously to the two ATP-related pathways. We thus used the
383 intersection and not the union of these two pathways. Advantage of this strategy was to
384 limit the number of SNPs to be tested, leading to a reduction of the multiple testing
385 burden and to a gain of power. Furthermore, after the analysis in the discovery sample
386 (EGEA), we used two different replication analyses of top EGEA results: first analysis
387 in the SLSJ sample, and then a combined analysis in the two samples (EGEA and
388 SLSJ). Although these two types of analyses are not independent (indeed combined

389 analysis of EGEA and SLSJ included SLSJ results), they led to detect two different
390 genes, that appear both interesting. Note that the *DNAH9* gene evidenced by our
391 previous positional cloning study [14] was also detected in the present study, ranked as
392 the third top SNP and as the 4th top gene, although results did not reach significance.

393 To our knowledge, none of our findings has been previously reported by published
394 GWAS (GWAS-Catalog of Published Genome-Wide Association Studies,
395 <http://genome.gov/gwastudies>), or by GEWIS for asthma, BHR or lung function.

396 Although a few G x ETS interaction studies [16, 18] have been published for BHR to
397 date, neither the *ATP8A1* nor the *ABCA1* genes have been mentioned.

398 The *ATP8A1* gene codes for a putative aminophospholipid transporting enzyme which
399 helps to maintain phospholipid asymmetry in cell membranes [38]. Recently, in non-
400 small-cell lung cancer, *ATP8A1* was found to be a novel direct target of miR-140-3p
401 [39], a small noncoding RNA molecule known to regulate gene expression, and that
402 may contribute substantially to airway epithelium abnormalities [40]. Moreover,
403 exposure of rats to cigarette smoke causes extensive alterations in miRNA expression of
404 the miR-140 family in the lung [41]. The *ABCA1* gene encodes a transport protein
405 known to participate to the maintenance of lung lipid homeostasis by interacting with
406 the apolipoprotein A-I (apoA-I), and which expression and function are affected by
407 smoking [42]. The critical role of ABCA1 in lung inflammation was evidenced from
408 murine knockout models [20] and a recent review reported that the apoA-I/ABCA1
409 pathway was involved in the modulation of the function of airway structural cells, and
410 associated with neutrophilic airway inflammation and airway hyperresponsiveness [43].
411 Furthermore, rs17448506 located in *ATP8A1* and rs2253304 in *ABCA1* are both intronic
412 variants, and map near regulatory elements and transcription factor binding sites

413 include that of NF-kappaB, an important participant in a broad spectrum of
414 inflammatory networks that regulate cytokine activity in airway pathology [44]. Lastly,
415 tobacco smoke pollution and soot have been reported to modify the expression of
416 *ATP8A1* and *ABCA1* mRNA.

417 Interestingly, some of the previous genes detected to interact with ETS in BHR, belong
418 to or interact experimentally with genes belonging to the “*ATPase activity*” or “*ATP*
419 *binding*” pathways. Among them, the *ADRB2* gene [9] belongs to the “*ATPase activity*”
420 pathway. The *PCDH1* gene [6] was shown to interact with *ABCA2* and *ATF7IP* genes,
421 which both belong to “*ATP binding*” and/or “*ATPase activity*” pathways. Similarly the
422 *PACRG* and the *EPB41L3* genes [12] were also shown to interact with numerous genes
423 belonging to “*ATP binding*” and/or “*ATPase activity*” pathways. Overall, all these data
424 suggest that *ATP8A1* and *ABCA1* may play a role in BHR in relationship with early
425 tobacco smoke exposure.

426 In conclusion, the present study highlights that G x E interaction analyses under a
427 pathway-based strategy allowed to identify promising candidate genes interacting with
428 ETS exposure in BHR susceptibility. Further confirmation of the interaction of *ATP8A1*
429 and *ABCA1* with ETS exposure as well as functional studies are needed to bring greater
430 insight into the role of these genes in BHR. Our study suggest that the two pathways are
431 promising to be further explored in the search of more effective therapies for
432 inflammatory lung diseases, especially for BHR that is a feature and an important risk
433 factor for asthma.

434

435 **COMPETING INTERESTS**

436 ‘None declared’

437

438 **CONTRIBUTORSHIP STATEMENT**

439 MHD and RN conducted the design. MHD and PMJ performed data analysis, N. MHD
440 and RN interpreted the findings and drafted the initial version of the manuscript. JJ, CL,
441 ML, FD, EB and MHD contributed to the data acquisition. FD and EB revised the
442 manuscript and all authors provided final approval of the version to be published.

443

444 **ACKNOWLEDGMENTS**

445

446 The authors declare they have no actual or potential competing financial interests.

447

448 We thank Inserm, the French Ministry of Higher Education and Research, University
449 Paris Diderot for supporting our research and the EGEA cooperative group:

450 **EGEA cooperative group**

451 **Coordination:** V Siroux (epidemiology, PI since 2013); F Demenais (genetics); I Pin
452 (clinical aspects); R Nadif (biology); F Kauffmann (PI 1992-2012).

453 **Respiratory epidemiology:** Inserm ex-U 700, Paris: M Korobaëff (Egea1), F Neukirch
454 (Egea1); Inserm ex-U 707, Paris: I Annesi-Maesano (Egea1-2); Inserm ex-U 1018,
455 Villejuif: F Kauffmann, MP Oryszczyn (Egea1-2); Inserm U 1168, Villejuif: N Le
456 Moual, R Nadif, R Varraso; Inserm U 1209 Grenoble: V Siroux.

457 **Genetics:** Inserm ex-U 393, Paris: J Feingold; Inserm U 946, Paris: E Bouzigon, F
458 Demenais, MH Dizier; CNG, Evry: I Gut (now CNAG, Barcelona, Spain), M Lathrop
459 (now Univ McGill, Montreal, Canada).

460 **Clinical centers:** Grenoble: I Pin, C Pison; Lyon: D Ecochard (Egea1), F Gormand, Y
461 Pacheco; Marseille: D Charpin (Egea1), D Vervloet (Egea1-2); Montpellier: J
462 Bousquet; Paris Cochin: A Lockhart (Egea1), R Matran (now in Lille); Paris Necker: E
463 Paty (Egea1-2), P Scheinmann (Egea1-2); Paris-Trousseau: A Grimfeld (Egea1-2), J
464 Just.

465 **Data and quality management:** Inserm ex-U155 (Egea1): J Hochez; Inserm U 1168,
466 Villejuif: N Le Moual; Inserm ex-U780: C Ravault (Egea1-2); Inserm ex-U794: N
467 Chateigner (Egea1-2); Grenoble: J Quentin (Egea1-2).

468 **SLSJ:** The author thanks all participants included in the SLSJ asthma familial
469 collection. C. Laprise is the Chairholder of the Canada Research Chair on Genetic
470 Determinants in Asthma (<http://www.chairs-chaire.gc.ca>), the director of the
471 Inflammation and Remodeling Strategic Group of the Respiratory Health Network of
472 the FRQS (<http://rsr.chus.qc.ca>) and member of the AllerGen (<http://www.allergen->
473 [nce.ca/](http://www.allergen-nce.ca/)).

474

475 **FUNDINGS**

476 The French EGEA study was partly funded by grants from the French National Agency
477 for Research (ANR 05-SEST-020-02/05-9-97, ANR 06-CEBS, ANR-11-BSV1-027-
478 GWIS-AM). Genotyping of the asthma-ascertained samples was supported by grants
479 from the European Commission (018996), the French Ministry of Higher Education and
480 Research. We also acknowledge Region Ile de France (DIM-SEnT 2011) and Fondation
481 pour la recherche Médicale (FRM 2013) for their support. The Canada Research Chair
482 on Genetic Determinants of Asthma held by C. Laprise since 2005 allows the
483 maintenance of the French Canadian study.

484

485

References

- 486
487
- 488 1 Rage E, Siroux V, Le Moual N, *et al.* Re: Are asymptomatic airway
489 hyperresponsiveness and allergy risk factors for asthma? A longitudinal study.
490 *Eur Respir J* 2009;**33**(1):218-9.
 - 491 2 March ME, Sleiman PM, Hakonarson H. Genetic polymorphisms and associated
492 susceptibility to asthma. *Int J Gen Med* 2013;**6**:253-65.
 - 493 3 Wjst M, Sargurupremraj M, Arnold M. Genome-wide association studies in
494 asthma: what they really told us about pathogenesis. *Curr Opin Allergy Clin
495 Immunol* 2013;**13**(1):112-8.
 - 496 4 Rava M, Ahmed I, Kogevinas M, *et al.* Genes Interacting with Occupational
497 Exposures to Low Molecular Weight Agents and Irritants on Adult-Onset
498 Asthma in Three European Studies. *Environ Health Perspect* 2017;**125**(2):207-
499 14.
 - 500 5 Ehrlich RI, Du Toit D, Jordaan E, *et al.* Risk factors for childhood asthma and
501 wheezing. Importance of maternal and household smoking. *Am J Respir Crit
502 Care Med* 1996;**154**(3 Pt 1):681-8.
 - 503 6 Koppelman GH, Meyers DA, Howard TD, *et al.* Identification of PCDH1 as a
504 novel susceptibility gene for bronchial hyperresponsiveness. *Am J Respir Crit
505 Care Med* 2009;**180**(10):929-35.
 - 506 7 Reijmerink NE, Kerkhof M, Koppelman GH, *et al.* Smoke exposure interacts
507 with ADAM33 polymorphisms in the development of lung function and
508 hyperresponsiveness. *Allergy* 2009;**64**(6):898-904.
 - 509 8 Bukvic BK, Blekic M, Simpson A, *et al.* Asthma severity, polymorphisms in
510 20p13 and their interaction with tobacco smoke exposure. *Pediatr Allergy
511 Immunol* 2013;**24**(1):10-8.
 - 512 9 Wang Z, Chen C, Niu T, *et al.* Association of asthma with beta(2)-adrenergic
513 receptor gene polymorphism and cigarette smoking. *Am J Respir Crit Care Med*
514 2001;**163**(6):1404-9.
 - 515 10 Bouzigon E, Corda E, Aschard H, *et al.* Effect of 17q21 variants and smoking
516 exposure in early-onset asthma. *N Engl J Med* 2008;**359**(19):1985-94.
 - 517 11 Moffatt MF, Kabesch M, Liang L, *et al.* Genetic variants regulating ORMDL3
518 expression contribute to the risk of childhood asthma. *Nature*
519 2007;**448**(7152):470-3.
 - 520 12 Scholtens S, Postma DS, Moffatt MF, *et al.* Novel childhood asthma genes
521 interact with in utero and early-life tobacco smoke exposure. *J Allergy Clin
522 Immunol* 2014;**133**(3):885-8.
 - 523 13 Dizier MH, Bouzigon E, Guilloud-Bataille M, *et al.* Evidence for gene x
524 smoking exposure interactions in a genome-wide linkage screen of asthma and
525 bronchial hyper-responsiveness in EGEA families. *Eur J Hum Genet*
526 2007;**15**(7):810-5.
 - 527 14 Dizier MH, Nadif R, Margaritte-Jeannin P, *et al.* Interaction between the
528 DNAH9 gene and early smoke exposure in bronchial hyperresponsiveness. *Eur
529 Respir J* 2016;**47**(4):1072-81.
 - 530 15 Sugier PE, Brossard M, Sarnowski C, *et al.* A novel role for cilia function in
531 atopy: ADGRV1 and DNAH5 interactions. *J Allergy Clin Immunol* 2017.
 - 532 16 King SM. Axonemal Dynein Arms. *Cold Spring Harb Perspect Biol* 2016;**8**(11).

- 533 17 Roberts AJ, Kon T, Knight PJ, *et al.* Functions and mechanics of dynein motor
534 proteins. *Nat Rev Mol Cell Biol* 2013;**14**(11):713-26.
- 535 18 Tilley AE, Walters MS, Shaykhiev R, *et al.* Cilia dysfunction in lung disease.
536 *Annu Rev Physiol* 2015;**77**:379-406.
- 537 19 Idzko M, Hammad H, van Nimwegen M, *et al.* Extracellular ATP triggers and
538 maintains asthmatic airway inflammation by activating dendritic cells. *Nat Med*
539 2007;**13**(8):913-9.
- 540 20 Chai AB, Ammit AJ, Gelissen IC. Examining the role of ABC lipid transporters
541 in pulmonary lipid homeostasis and inflammation. *Respir Res* 2017;**18**(1):41.
- 542 21 Houtmeyers E, Gosselink R, Gayan-Ramirez G, *et al.* Regulation of mucociliary
543 clearance in health and disease. *Eur Respir J* 1999;**13**(5):1177-88.
- 544 22 Huynh TP, Mah V, Sampson VB, *et al.* Na,K-ATPase is a target of cigarette
545 smoke and reduced expression predicts poor patient outcome of smokers with
546 lung cancer. *Am J Physiol Lung Cell Mol Physiol* 2012;**302**(11):L1150-8.
- 547 23 Padmavathi P, Reddy VD, Maturu P, *et al.* Smoking-induced alterations in
548 platelet membrane fluidity and Na(+)/K(+)-ATPase activity in chronic cigarette
549 smokers. *J Atheroscler Thromb* 2010;**17**(6):619-27.
- 550 24 Horvath S, Xu X, Laird NM. The family based association test method:
551 strategies for studying general genotype--phenotype associations. *Eur J Hum*
552 *Genet* 2001;**9**(4):301-6.
- 553 25 Umbach DM, Weinberg CR. The use of case-parent triads to study joint effects
554 of genotype and exposure. *Am J Hum Genet* 2000;**66**(1):251-61.
- 555 26 Kauffmann F, Dizier MH, Pin I, *et al.* Epidemiological study of the genetics and
556 environment of asthma, bronchial hyperresponsiveness, and atopy: phenotype
557 issues. *Am J Respir Crit Care Med* 1997;**156**(4 Pt 2):S123-9.
- 558 27 Laprise C. The Saguenay-Lac-Saint-Jean asthma familial collection: the genetics
559 of asthma in a young founder population. *Genes Immun* 2014;**15**(4):247-55.
- 560 28 Moffatt MF, Gut IG, Demenais F, *et al.* A large-scale, consortium-based
561 genomewide association study of asthma. *N Engl J Med* 2010;**363**(13):1211-21.
- 562 29 Lake SL, Blacker D, Laird NM. Family-based tests of association in the
563 presence of linkage. *Am J Hum Genet* 2000;**67**(6):1515-25.
- 564 30 Dizier MH, Margaritte-Jeannin P, Madore AM, *et al.* The nuclear factor I/A
565 (NFIA) gene is associated with the asthma plus rhinitis phenotype. *J Allergy*
566 *Clin Immunol* 2014;**134**(3):576-82 e1.
- 567 31 Li J, Ji L. Adjusting multiple testing in multilocus analyses using the
568 eigenvalues of a correlation matrix. *Heredity (Edinb)* 2005;**95**(3):221-7.
- 569 32 Liu JZ, McRae AF, Nyholt DR, *et al.* A versatile gene-based test for genome-
570 wide association studies. *Am J Hum Genet* 2010;**87**(1):139-45.
- 571 33 Gibson G. Human genetics. GTEx detects genetic effects. *Science*
572 2015;**348**(6235):640-1.
- 573 34 Davis AP, Grondin CJ, Lennon-Hopkins K, *et al.* The Comparative
574 Toxicogenomics Database's 10th year anniversary: update 2015. *Nucleic Acids*
575 *Res* 2015;**43**(Database issue):D914-20.
- 576 35 Blekic M, Kljaic Bukvic B, Aberle N, *et al.* 17q12-21 and asthma: interactions
577 with early-life environmental exposures. *Ann Allergy Asthma Immunol*
578 2013;**110**(5):347-53 e2.
- 579 36 Allen L, Williams J, Townsend N, *et al.* Socioeconomic status and non-
580 communicable disease behavioural risk factors in low-income and lower-

- 581 middle-income countries: a systematic review. *Lancet Glob Health*
582 2017;**5**(3):e277-e89.
- 583 37 Kuntz B, Lampert T. Social disparities in parental smoking and young children's
584 exposure to secondhand smoke at home: a time-trend analysis of repeated cross-
585 sectional data from the German KiGGS study between 2003-2006 and 2009-
586 2012. *BMC Public Health* 2016;**16**:485.
- 587 38 Sobocki T, Jayman F, Sobocka MB, *et al.* Isolation, sequencing, and functional
588 analysis of the TATA-less murine ATPase II promoter and structural analysis of
589 the ATPase II gene. *Biochim Biophys Acta* 2007;**1769**(1):61-75.
- 590 39 Dong W, Yao C, Teng X, *et al.* MiR-140-3p suppressed cell growth and
591 invasion by downregulating the expression of ATP8A1 in non-small cell lung
592 cancer. *Tumour Biol* 2016;**37**(3):2973-85.
- 593 40 Moheimani F, Hsu AC, Reid AT, *et al.* The genetic and epigenetic landscapes of
594 the epithelium in asthma. *Respir Res* 2016;**17**(1):119.
- 595 41 Izzotti A, Calin GA, Arrigo P, *et al.* Downregulation of microRNA expression
596 in the lungs of rats exposed to cigarette smoke. *FASEB J* 2009;**23**(3):806-12.
- 597 42 Jubinville E, Talbot M, Berube JC, *et al.* Interplay between cigarette smoking
598 and pulmonary reverse lipid transport. *Eur Respir J* 2017;**50**(3).
- 599 43 Yao X, Gordon EM, Barochia AV, *et al.* The A's Have It: Developing
600 Apolipoprotein A-I Mimetic Peptides Into a Novel Treatment for Asthma. *Chest*
601 2016;**150**(2):283-8.
- 602 44 Schuliga M. NF-kappaB Signaling in Chronic Inflammatory Airway Disease.
603 *Biomolecules* 2015;**5**(3):1266-83.
604
605
606